Skip to main content
Erschienen in: Clinical & Experimental Metastasis 4/2012

01.04.2012 | Research Paper

Augmented autocrine bone morphogenic protein (BMP) 7 signaling increases the metastatic potential of mouse breast cancer cells

verfasst von: Hirofumi Sakai, Mutsuo Furihata, Chie Matsuda, Munehisa Takahashi, Hiroshi Miyazaki, Takeo Konakahara, Toru Imamura, Tomoko Okada

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

As malignant breast cancers progress, they acquire the ability to spread to other regions of the body, including bone and lung, but the molecular mechanism underlying the increase in metastatic potential is not fully understood. Here we studied murine 4T1E/M3 highly bone marrow metastatic breast cancer cells, which we established previously. These cells show upregulated expression of bone morphogenetic protein (BMP) 7 and BMP receptors, as well as augmented phosphorylation of Smad1/5/8. Both anchorage-independent cell growth measured in colony forming assays and cell migration measured in wound healing assays were suppressed in 4T1E/M3 cells following treatment with a neutralizing anti-BMP7 antibody or knockdown of BMP7 gene expression. In addition, metastasis of 4T1E/M3 cells to the spine and lung and intracellular levels of phosphorylated Smad1/5/8 were suppressed by knocking down BMP7. Conversely, overexpression of BMP7 in the weakly metastatic parental 4T1E cells augmented their anchorage-independent growth, migration and metastasis to spine and lung. Taken together, our results strongly suggest that augmented autocrine BMP7 signaling leads to increases in the anchorage-independent cell growth, migration and metastatic potential in our bone marrow metastatic breast cancer model.
Literatur
1.
Zurück zum Zitat Takahashi M, Furihata M, Akimitsu N, Watanabe M, Kaul S, Yumoto N, Okada T (2008) A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1. Clin Exp Metastasis 25:517–529PubMedCrossRef Takahashi M, Furihata M, Akimitsu N, Watanabe M, Kaul S, Yumoto N, Okada T (2008) A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1. Clin Exp Metastasis 25:517–529PubMedCrossRef
2.
Zurück zum Zitat Takahashi M, Miyazaki H, Furihata M, Sakai H, Konakahara T, Watanabe M, Okada T (2009) Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastasis 26:817–828PubMedCrossRef Takahashi M, Miyazaki H, Furihata M, Sakai H, Konakahara T, Watanabe M, Okada T (2009) Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastasis 26:817–828PubMedCrossRef
3.
Zurück zum Zitat Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 4:233–241CrossRef Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 4:233–241CrossRef
4.
Zurück zum Zitat Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG (2007) Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 10:1129–1147 Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG (2007) Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 10:1129–1147
5.
Zurück zum Zitat Asahina I, Sampath TK, Hauschka PV (1996) Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Exp Cell Res 222:38–47PubMedCrossRef Asahina I, Sampath TK, Hauschka PV (1996) Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Exp Cell Res 222:38–47PubMedCrossRef
6.
Zurück zum Zitat Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC (1998) Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 78:1219–1223PubMedCrossRef Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC (1998) Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 78:1219–1223PubMedCrossRef
7.
Zurück zum Zitat Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, Yamanaka H (2003) Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54:268–274PubMedCrossRef Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, Yamanaka H (2003) Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54:268–274PubMedCrossRef
8.
Zurück zum Zitat Miyazono K, Kamiya Y, Morikawa M (2010) Bone morphogenetic protein receptors and signal transduction. J Biochem 147:35–51PubMedCrossRef Miyazono K, Kamiya Y, Morikawa M (2010) Bone morphogenetic protein receptors and signal transduction. J Biochem 147:35–51PubMedCrossRef
9.
Zurück zum Zitat Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K (2002) Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 12:1191–1204CrossRef Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K (2002) Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 12:1191–1204CrossRef
10.
Zurück zum Zitat Massagué J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295–309PubMedCrossRef Massagué J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295–309PubMedCrossRef
11.
Zurück zum Zitat Asada M, Honda E, Imamura T (2006) Construction of pcDNA 3.1-based vectors with blasticidin and puromycin resistant markers. Anal Biochem 352:305–307PubMedCrossRef Asada M, Honda E, Imamura T (2006) Construction of pcDNA 3.1-based vectors with blasticidin and puromycin resistant markers. Anal Biochem 352:305–307PubMedCrossRef
12.
Zurück zum Zitat Alarmo EL, Pärssinen J, Ketolainen JM, Savinainen K, Karhu R, Kallioniemi A (2009) BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett 275:35–43PubMedCrossRef Alarmo EL, Pärssinen J, Ketolainen JM, Savinainen K, Karhu R, Kallioniemi A (2009) BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett 275:35–43PubMedCrossRef
13.
Zurück zum Zitat Ichikawa T, Suenaga Y, Koda T, Ozaki T, Nakagawara A (2008) DeltaNp63/BMP-7-dependent expression of matrilin-2 is involved in keratinocyte migration in response to wounding. Biochem Biophys Res Commun 369:994–1000PubMedCrossRef Ichikawa T, Suenaga Y, Koda T, Ozaki T, Nakagawara A (2008) DeltaNp63/BMP-7-dependent expression of matrilin-2 is involved in keratinocyte migration in response to wounding. Biochem Biophys Res Commun 369:994–1000PubMedCrossRef
14.
Zurück zum Zitat Rothhammer T, Braig S, Bosserhoff AK (2008) Bone morphogenetic proteins induce expression of metalloproteinases in melanoma cells and fibroblasts. Eur J Cancer 44:2526–2534PubMedCrossRef Rothhammer T, Braig S, Bosserhoff AK (2008) Bone morphogenetic proteins induce expression of metalloproteinases in melanoma cells and fibroblasts. Eur J Cancer 44:2526–2534PubMedCrossRef
15.
Zurück zum Zitat Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964–968PubMedCrossRef Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964–968PubMedCrossRef
16.
Zurück zum Zitat Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC (2006) In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res 66:9583–9590PubMedCrossRef Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC (2006) In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res 66:9583–9590PubMedCrossRef
17.
Zurück zum Zitat Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P (2005) Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 65:5769–5777PubMedCrossRef Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P (2005) Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 65:5769–5777PubMedCrossRef
18.
Zurück zum Zitat Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK (2005) Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65:448–456PubMed Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK (2005) Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65:448–456PubMed
19.
Zurück zum Zitat Alarmo EL, Korhonen T, Kuukasjärvi T, Huhtala H, Holli K, Kallioniemi A (2008) Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas. Ann Oncol 19:308–314PubMedCrossRef Alarmo EL, Korhonen T, Kuukasjärvi T, Huhtala H, Holli K, Kallioniemi A (2008) Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas. Ann Oncol 19:308–314PubMedCrossRef
20.
Zurück zum Zitat Motoyama K, Tanaka F, Kosaka Y, Mimori K, Uetake H, Inoue H, Sugihara K, Mori M (2008) Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol 15:1530–1537PubMedCrossRef Motoyama K, Tanaka F, Kosaka Y, Mimori K, Uetake H, Inoue H, Sugihara K, Mori M (2008) Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol 15:1530–1537PubMedCrossRef
21.
Zurück zum Zitat Rothhammer T, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, Hein R, Hofstaedter F, Bosserhoff AK (2007) Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma. Cancer Biomark 3:111–117PubMed Rothhammer T, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, Hein R, Hofstaedter F, Bosserhoff AK (2007) Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma. Cancer Biomark 3:111–117PubMed
22.
Zurück zum Zitat Buijs JT, Henriquez NV, van Overveld PG (2007) Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67:8742–8751PubMedCrossRef Buijs JT, Henriquez NV, van Overveld PG (2007) Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67:8742–8751PubMedCrossRef
23.
Zurück zum Zitat Na YR, Seok SH, Kim DJ et al (2009) Bone morphogenetic protein 7 induces mesenchymal -to-epithelial transition in melanoma cells, leading to inhibition of metastasis. Cancer Sci 100:2218–2225PubMedCrossRef Na YR, Seok SH, Kim DJ et al (2009) Bone morphogenetic protein 7 induces mesenchymal -to-epithelial transition in melanoma cells, leading to inhibition of metastasis. Cancer Sci 100:2218–2225PubMedCrossRef
24.
Zurück zum Zitat Chen J, Ye L, Xie F, Yang Y, Zhang L, Jiang WG (2010) Expression of bone morphogenetic protein 7 in lung cancer and its biological impact on lung cancer cells. Anticancer Res 4:1113–1120 Chen J, Ye L, Xie F, Yang Y, Zhang L, Jiang WG (2010) Expression of bone morphogenetic protein 7 in lung cancer and its biological impact on lung cancer cells. Anticancer Res 4:1113–1120
25.
Zurück zum Zitat Uruno T, Oki J, Ozawa K, Miyakawa K, Ueno H, Imamura T (1999) Distinct regulation of myoblast differentiation by intracellular and extracellular fibroblast growth factor-1. Growth Factors 17:93–113PubMedCrossRef Uruno T, Oki J, Ozawa K, Miyakawa K, Ueno H, Imamura T (1999) Distinct regulation of myoblast differentiation by intracellular and extracellular fibroblast growth factor-1. Growth Factors 17:93–113PubMedCrossRef
26.
Zurück zum Zitat Schoner W, Scheiner-Bobis G (2007) Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 293:C509–C536PubMedCrossRef Schoner W, Scheiner-Bobis G (2007) Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 293:C509–C536PubMedCrossRef
27.
Zurück zum Zitat Fournier PG, Guise TA (2007) BMP7: a new bone metastases prevention? Am J Pathol 171:739–743PubMedCrossRef Fournier PG, Guise TA (2007) BMP7: a new bone metastases prevention? Am J Pathol 171:739–743PubMedCrossRef
28.
Zurück zum Zitat Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E (2010) Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia 12:192–205PubMed Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E (2010) Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia 12:192–205PubMed
Metadaten
Titel
Augmented autocrine bone morphogenic protein (BMP) 7 signaling increases the metastatic potential of mouse breast cancer cells
verfasst von
Hirofumi Sakai
Mutsuo Furihata
Chie Matsuda
Munehisa Takahashi
Hiroshi Miyazaki
Takeo Konakahara
Toru Imamura
Tomoko Okada
Publikationsdatum
01.04.2012
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 4/2012
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-012-9453-9

Weitere Artikel der Ausgabe 4/2012

Clinical & Experimental Metastasis 4/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.